CPGJ602

BIOLOGICAL2 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions

Metastatic Colorectal Cancer

Phase 1

A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Metastatic Colorectal Cancer

Start: 2017-11-15End: 2018-11-30Target: 21Updated: 2018-09-17

Phase 2

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Metastatic Colorectal Cancer

Start: 2020-12-07End: 2022-03-30Target: 75Updated: 2021-08-23

Related Papers

CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.

Journal of Clinical Oncology2022-06-01